1-(4-Fluorophenyl)-2-(4-(methylsulfonyl)phenyl)ethanone | 132470-25-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 1-(4-Fluorophenyl)-2-(4-(methylsulfonyl)phenyl)ethanone
• 英文别名: 1-(4-fluorophenyl)-2-[4-(methylsulfonyl)phenyl]ethanone；1-(4-fluorophenyl)-2-(4-methanesulfonylphenyl)ethanone；1-(4-fluorophenyl)-2-(4-methylsulfonyl-phenyl)-ethanone；1-(4-fluorophenyl)-2-(4-methylsulfonylphenyl)ethanone
• CAS: 132470-25-8
• 化学式: C₁₅H₁₃FO₃S
• 分子量: 292.331
• InChiKey: FHRZPTXMKRPRQF-UHFFFAOYSA-N

物化性质

• 沸点：
  483.6±45.0 °C(Predicted)
• 密度：
  1.284±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  59.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(4-Fluorophenyl)-2-(4-(methylsulfonyl)phenyl)ethanone 在 三氯氧磷 作用下， 以 乙醚 、 正己烷 、 氯仿 、 N,N-二甲基甲酰胺 为溶剂， 生成 3-chloro-3-(4-fluorophenyl)-2-(4-methylsulfonylphenyl)acrylaldehyde
  参考文献：
  名称：

  3-halogeno-2,3-diphenylacrylaldehyde derivatives, process for preparing

  摘要：

  本发明涉及一种由下式表示的3-卤代-2,3-二苯基丙烯醛衍生物：##STR1## 其中R是具有1至6个碳原子的烷基，X和Y分别表示卤素原子，n为0、1或2；以及一种制备该衍生物的方法，一种包含药理学有效量的该衍生物的用于预防和治疗高脂血症的药物，以及一种使用该药物预防或治疗高脂血症的方法。

  公开号：

  US05082974A1
• 作为产物：
  描述：

  氟苯 在 三氯化铝 、 magnesium monoperoxyphthalate hexahydrate 作用下， 以 甲醇 、 二硫化碳 、 二氯甲烷 为溶剂， 反应 24.0h， 生成 1-(4-Fluorophenyl)-2-(4-(methylsulfonyl)phenyl)ethanone
  参考文献：
  名称：

  Synthesis and Biological Evaluation of 2-Phenylpyran-4-ones:  A New Class of Orally Active Cyclooxygenase-2 Inhibitors

  摘要：

  A series of 2-phenylpyran-4-ones were prepared and evaluated for their ability to inhibit cyclooxygenase-2 (COX-2). Extensive structure-activity relationship work was carried out within this series, and a number of potent and selective COX-2 inhibitors were identified. Compounds having a p-methylsulfone group at the 2-phenyl ring showed the best COX-2 inhibitory activity. The introduction of a substituted phenoxy ring at position 3 enhanced both the in vitro and in vivo activity within the series. A selected group of 3-phenoxypyran-4-ones exhibited excellent activity in an experimental model of pyresis. The in vivo antiinflammatory activity of these compounds was confirmed with the evaluation of their antiarthritic and analgesic effectiveness. Moreover, their pharmacokinetic profile in rats is compatible with a once a day administration by oral route in humans. Within this novel series, compounds 21, 31, 34, and 35 have been selected for further preclinical. and clinical evaluation.

  DOI：

  10.1021/jm049882t

文献信息

• Use of inhibitors of cyclooxygenase in the treatment of
  申请人：Merck Frosst Canada, Inc.

  公开号：US05840746A1

  公开（公告）日：1998-11-24

  The present invention provides a method of treating a neurodegenerative disease and in particular Alzheimers disease which comprises administering to a human in need thereof a therapeutically effective amount of a non-steroid COX-II inhibitor. Although a wide range of COX-II inhibitors may be employed but it is preferred to employ compounds of the Formula I: ##STR1##

  本发明提供了一种治疗神经退行性疾病，特别是阿尔茨海默病的方法，包括向需要的人类施用治疗有效量的非类固醇COX-II抑制剂。虽然可以使用各种COX-II抑制剂，但最好使用Formula I的化合物。
• Phenyl heterocycles as cox-2 inhibitors
  申请人：Merck Frosst Canada, Inc.

  公开号：US05474995A1

  公开（公告）日：1995-12-12

  The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases, ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.

  这项发明涵盖了化合物I的新颖结构，可用于治疗环氧合酶-2介导的疾病，##STR1## 该发明还涵盖了用于治疗环氧合酶-2介导疾病的某些药物组合物，其中包括化合物I。
• Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
  申请人：Merck Frosst Canada, Inc.

  公开号：US05521213A1

  公开（公告）日：1996-05-28

  The invention encompasses the novel compound of Formula I as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.

  该发明涵盖了公式I的新型化合物，以及一种治疗环氧合酶-2介导疾病的方法，包括向需要此类治疗的患者施用公式I化合物的非毒性治疗有效量。该发明还涵盖了某些用于治疗环氧合酶-2介导疾病的药物组合物，其中包括公式I的化合物。
• Substituted thiazoles for the treatment of inflammation
  申请人：G.D. Searle & Co.

  公开号：US05668161A1

  公开（公告）日：1997-09-16

  A class of substituted thiazolyl compounds is described for use in treating inflammation disorders. Compounds are defined by Formula II ##STR1## wherein R.sup.1 is selected from hydrido, alkyl, haloalkyl, cyanoalkyl, alkylamino, aralkyl, arylamino, heteroarylsulfonylalkyl, heteroarylsulfonylhaloalkyl, aralkylamino, aryloxyalkyl, alkoxycarbonyl, aryl optionally substituted at a substitutable position with one or more radicals selected from halo and alkoxy, and heterocyclic optionally substituted at a substitutable position with one or more radicals selected from halo and alkyl; wherein R.sup.4 is selected from alkyl and amino; and wherein R.sup.5 is selected from aryl and heteroaryl; wherein R.sup.5 is optionally substituted at a substitutable position with one or more radicals selected from halo, alkyl and alkoxy; provided R.sup.5 is not phenyl at position 4 when R.sup.1 is .alpha.,.alpha.-bis(trifluoromethyl)methanol and R.sup.4 is methyl; or a pharmaceutically-acceptable salt thereof.

  描述了一类取代噻唑基化合物，用于治疗炎症性疾病。这些化合物由公式II定义，其中R.sup.1从氢化物、烷基、卤代烷基、氰基烷基、烷基胺基、芳基烷基、芳基胺基、杂环磺酰基烷基、杂环磺酰基卤代烷基、芳基胺基、芳氧基烷基、烷氧羰基、芳基（在可取代位置上可用一个或多个卤素和烷氧基选择的基团）和杂环（在可取代位置上可用一个或多个卤素和烷基选择的基团）中选择；其中R.sup.4从烷基和氨基中选择；其中R.sup.5从芳基和杂环中选择；其中R.sup.5在可取代位置上可用一个或多个卤素、烷基和烷氧基选择的基团进行取代；只要R.sup.5不是苯基在位置4时，当R.sup.1是α,α-双（三氟甲基）甲醇且R.sup.4是甲基；或其药用可接受盐。
• Aryl substituted 5,5 fused aromatic nitrogen compounds as
  申请人：Merck Frosst Canada, Inc.

  公开号：US05552422A1

  公开（公告）日：1996-09-03

  The invention encompasses the novel compound of Formula I as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.

  该发明涵盖了公式I的新化合物，以及一种治疗环氧合酶-2介导疾病的方法，包括向需要该治疗的患者施用公式I化合物的非毒性治疗有效量。 该发明还涵盖了用于治疗环氧合酶-2介导疾病的某些药物组合，其中包括公式I的化合物。